Table 1 Baseline characteristics of patients in the TACERA study.
Characteristics | Baseline (n = 267) |
|---|---|
Age, years | 53.1 (15.2) |
Female | 192 (71.9%) |
White Ethnicity | 194 (72.7%) |
BMI | |
  Female | 27.53 (6.47) |
  Male | 27.43 (4.97) |
  Overall | 27.50 (6.08) |
BMI Status | |
  Underweight: <18.5 | 9 (3.4%) |
  Healthy weight: (18.5,25) | 85 (31.8%) |
  Overweight: (25,30) | 95 (35.6%) |
  Obese: ≥30 | 78 (29.2%) |
Smoking | |
  Never smoked | 95 (35.6%) |
  Previous smoker | 104 (39.0%) |
  Current smoker | 68 (25.4%) |
Alcohol consumption | |
  None | 86 (32.3%) |
  1–5 units per week | 115 (43.2%) |
  6–10 units per week | 25 (9.4%) |
  11–15 units per week | 11 (4.1%) |
  16–20 units per week | 15 (5.7%) |
  More than 20 units per week | 14 (5.3%) |
Alcohol frequency | |
  Not Drinking | 86 (32.2%) |
  1–2 days a year | 28 (10.5%) |
  1–2 days a month | 48 (18.0%) |
  1–2 days a week | 58 (21.7%) |
  3–4 days a week | 28 (10.5%) |
  5 days or more a week | 19 (7.1%) |
Rheumatoid Factor (RF) positive | 247 (92.5%) |
Anti-citrullinated protein antibody (ACPA) positive | 230 (86.1%) |
Disease Duration (years) | 0.43 (0.23) |
X-ray Larsen’s Score (hands and feet) | 6.70 (8.76) |
Charlson’s Comorbidity Index (original) | 0.44 (0.84) |
Charlson’s Comorbidity Index (2008) | 0.81 (1.10) |
SDAI | 28.80 (14.29) |
DAS28-CRP | 4.85 (1.22) |
Prescribed Medication | |
  Methotrexate (MTX) | 202 (75.7%) |
  Hydroxychloroquine | 141 (52.8%) |
  Leflunomide | 0 (0.0%) |
  Sulfasalazine | 18 (6.7%) |
  Oral glucocorticoids | 17 (6.4%) |
  Parenteral glucocorticoids | 126 (47.2%) |
  No RA medication | 2 (0.7%) |
Medication combinations prescribed | |
  No RA medication | 2 (0.7%) |
  MTX only | 51 (19.1%) |
  Other DMARDs only | 20 (7.5%) |
  Oral glucocorticoids only | 2 (0.7%) |
  Parenteral glucocorticoids only | 15 (5.6%) |
  MTX & other DMARDs | 53 (19.9%) |
  MTX & oral glucocorticoids | 6 (2.2%) |
  MTX & parenteral glucocorticoids | 33 (12.4%) |
  Other DMARDs & oral glucocorticoids | 2 (0.7%) |
  Other DMARDs & parenteral glucocorticoids | 23 (8.6%) |
  Oral & parenteral glucocorticoids | 1 (0.4%) |
  MTX, other DMARDs & oral glucocorticoids | 5 (1.9%) |
  MTX, other DMARDs & parenteral glucocorticoids | 53 (19.9%) |
  MTX, oral & parenteral glucocorticoids | 1 (0.4%) |
